Open Access Perspective Article ID: JSSR-1-119

    EGFR Inhibitors for Neoadjuvant and Adjuvant Therapy of NSCLC

    Fabio Villa*

    5-year survival rates of Non-Small Cell Lung Cancer (NSCLC) remain unsatisfactory after surgery with curative intent and disease recurrences, including distant metastases, are frequent. Only a minority of this heterogeneous disease is positive for EGFR mutations and suitable for Tyrosine Kinase-Inhibitor biological agents, which however present limits in terms of stable response to treatment, due to the acquired drug resistances. A few trials administrating EGFR inhibitors combined with surgery, in neoadjuvant or adjuvant settings, have been reported with lack of evidence. The third-generation EGFR inhibitors, with the amelioration of techniques of gene profiling and the knowledge of pathways could extent the spectrum of complementary-to-surgery treatments in NSCLC at high risk of relapse.


    Published on: Dec 17, 2015 Pages: 78-79

    Full Text PDF Full Text HTML DOI: 10.17352/2455-2968.000019
    Get Citation Base Search Scilit OAI-PMH ResearchGate GrowKudos CrossMark

    Global Views

    Case Reports

    Peertechz Tweets

    Pinterest on JSSR